An Open, Uncontrolled Pilot Study on 12-Week Use of VagiVital for Treatment of Vulvovaginal Atrophy in Breast Cancer Patients Undergoing Adjuvant Aromatase-Inhibitor Therapy
Aino Fianu Jonasson,1 Mikael Åstrom2 1Department of Clinical Sciences, Intervention, and Technology, Division of Obstetrics and Gynaecology, Karolinska Institute, Stockholm, Sweden; 2StatCons, Malmö, SwedenCorrespondence: Aino Fianu JonassonDepartment of Clinical Science, Intervention and Technology...
Guardado en:
Autores principales: | Jonasson AF, Åstrom M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a66ce6c9800426b892f310b8fb48547 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital® Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study
por: Fianu Jonasson A, et al.
Publicado: (2020) -
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz GT, et al.
Publicado: (2014) -
A New Therapy for Uncomplicated Vulvovaginal Candidiasis and Its Impact on Vaginal Flora
por: Guglielmo Stabile, et al.
Publicado: (2021) -
Manejo de la atrofia vulvovaginal posmenopáusica
por: Monterrosa-Castro,Alvaro, et al.
Publicado: (2014) -
Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
por: Ana Paula Ferreira Costa, et al.
Publicado: (2021)